Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Standard
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. / Müller, Volkmar; Riethdorf, Sabine; Rack, Brigitte; Janni, Wolfgang; Fasching, Peter A; Solomayer, Erich; Aktas, Bahriye; Kasimir-Bauer, Sabine; Pantel, Klaus; Fehm, Tanja; Group, On Behalf Of The DETECT Study.
In: BREAST CANCER RES, Vol. 14, No. 4, 4, 2012, p. 118.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
AU - Müller, Volkmar
AU - Riethdorf, Sabine
AU - Rack, Brigitte
AU - Janni, Wolfgang
AU - Fasching, Peter A
AU - Solomayer, Erich
AU - Aktas, Bahriye
AU - Kasimir-Bauer, Sabine
AU - Pantel, Klaus
AU - Fehm, Tanja
AU - Group, On Behalf Of The DETECT Study
PY - 2012
Y1 - 2012
N2 - ABSTRACT: INTRODUCTION: There is a multitude of assays for the detection of circulating tumor cells (CTCs) but a very limited number of studies comparing the clinical relevance of results obtained with different test methods. The DETECT trial for metastatic breast cancer patients was designed to directly compare the prognostic impact of two commercially available CTC assays that are prominent representatives of immunocytochemical and RT-PCR based technologies. METHODS: In total, 254 metastatic breast cancer patients were enrolled in this prospective multicenter trial. CTCs were assessed using both the AdnaTest Breast Cancer and the CellSearch system according to the manufacturers' instructions. RESULTS: With the CellSearch system, 116 of 221 (50%) evaluable patients were CTC-positive based on a cut-off level at 5 or more CTCs. The median overall survival (OS) was 18.1 months in CTC-positive patients. (95%-CI: 15.1-22.1 months) compared to 27 months in CTC-negative patients (23.5-30.7 months; p
AB - ABSTRACT: INTRODUCTION: There is a multitude of assays for the detection of circulating tumor cells (CTCs) but a very limited number of studies comparing the clinical relevance of results obtained with different test methods. The DETECT trial for metastatic breast cancer patients was designed to directly compare the prognostic impact of two commercially available CTC assays that are prominent representatives of immunocytochemical and RT-PCR based technologies. METHODS: In total, 254 metastatic breast cancer patients were enrolled in this prospective multicenter trial. CTCs were assessed using both the AdnaTest Breast Cancer and the CellSearch system according to the manufacturers' instructions. RESULTS: With the CellSearch system, 116 of 221 (50%) evaluable patients were CTC-positive based on a cut-off level at 5 or more CTCs. The median overall survival (OS) was 18.1 months in CTC-positive patients. (95%-CI: 15.1-22.1 months) compared to 27 months in CTC-negative patients (23.5-30.7 months; p
U2 - 10.1186/bcr3243
DO - 10.1186/bcr3243
M3 - SCORING: Journal article
VL - 14
SP - 118
JO - BREAST CANCER RES
JF - BREAST CANCER RES
SN - 1465-5411
IS - 4
M1 - 4
ER -
